Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04915508 | Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy(EXCALIBUR) | active not recruiting | Phase 2 | 165 | Jonsson Comprehensive Cancer CenterOTHER | 1 |
| Jul 17, 2026 |
| clinicaltrials |
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05465941 | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | active not recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05607004 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer(EVANGELINE) | active not recruiting | Phase 2 | 87 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | active not recruiting | Phase 2 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | active not recruiting | Phase 2 | 46 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | active not recruiting | Phase 2 | 280 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT01950351 | Hypofractionated Proton Beam Therapy for Localized Prostate Cancer | active not recruiting | Phase 2 | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06494150 | Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) | active not recruiting | Phase 2 | 37 | University of OklahomaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | active not recruiting | Phase 2 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04190446 | A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer | active not recruiting | Phase 2 | 84 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07341100 | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC | active not recruiting | Phase 2 | 20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05496959 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study(LUNAR) | active not recruiting | Phase 2 | 93 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00544830 | Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03609216 | Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | active not recruiting | Phase 2 | 237 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 46 | Matthew GalskyOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05335993 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | active not recruiting | Phase 2 | 10 | CanariaBio Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 88 | CanariaBio Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 23, 2026source: clinicaltrials